XOMA Co. (NASDAQ:XOMA – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $16.83 and traded as high as $17.57. XOMA shares last traded at $16.26, with a volume of 15,235 shares traded.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. StockNews.com assumed coverage on shares of XOMA in a report on Thursday, October 5th. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating and set a $74.00 price target on shares of XOMA in a research report on Wednesday, September 13th.
XOMA Price Performance
XOMA (NASDAQ:XOMA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.07). The company had revenue of $1.66 million for the quarter, compared to analyst estimates of $1.70 million. XOMA had a negative return on equity of 22.33% and a negative net margin of 663.07%. Equities research analysts forecast that XOMA Co. will post -2.5 EPS for the current fiscal year.
Institutional Trading of XOMA
Institutional investors have recently added to or reduced their stakes in the business. Knott David M Jr lifted its stake in XOMA by 18.4% in the first quarter. Knott David M Jr now owns 13,527 shares of the biotechnology company’s stock valued at $286,000 after acquiring an additional 2,102 shares during the last quarter. California State Teachers Retirement System acquired a new stake in XOMA in the second quarter valued at approximately $46,000. Bank of America Corp DE lifted its stake in XOMA by 40.7% in the fourth quarter. Bank of America Corp DE now owns 2,380 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 689 shares during the last quarter. BNP Paribas Arbitrage SNC acquired a new stake in XOMA in the second quarter valued at approximately $36,000. Finally, Barclays PLC acquired a new stake in XOMA in the second quarter valued at approximately $28,000. 65.35% of the stock is currently owned by institutional investors and hedge funds.
XOMA Company Profile
XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.
- Five stocks we like better than XOMA
- Short Selling: How to Short a Stock
- GSK is a remedy for the winter investment blahs
- Why Consider Investing in Nanotechnology Stocks
- After blowout earnings, Integer may be headed to new highs
- What is a SEC Filing?
- Banking and trucking: Is the economy rolling toward troubles?
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.